Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amylyx Pharmaceuticals, Inc. - Common Stock
(NQ:
AMLX
)
1.730
-0.050 (-2.81%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amylyx Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Here's How Citi Views Amylyx Pharma
June 14, 2022
Via
Benzinga
What 4 Analyst Ratings Have To Say About Amylyx Pharma
June 14, 2022
Within the last quarter, Amylyx Pharma (NASDAQ:AMLX) has observed the following analyst ratings:
Via
Benzinga
Canada Approves Amylyx's ALS Drug; FDA To Consider Approval In September
June 13, 2022
The Canadian government has given its approval to AMX0035, a new drug from Cambridge, Massachusetts-based Amylyx Pharmaceuticals Inc.
Via
Benzinga
Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS
June 13, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Mid-Afternoon Market Update: Gold Drops 1%; Sprague Resources Shares Spike Higher
June 03, 2022
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 300 points on Friday.
Via
Benzinga
Expert Ratings For Amylyx Pharmaceuticals
April 01, 2022
Within the last quarter, Amylyx Pharmaceuticals (NASDAQ:AMLX) has observed the following analyst ratings:
Via
Benzinga
83 Biggest Movers From Yesterday
June 09, 2022
Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly...
Via
Benzinga
Why Stealth BioTherapeutics Shares Are Surging Today?
June 08, 2022
Via
Benzinga
69 Biggest Movers From Friday
June 06, 2022
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per...
Via
Benzinga
Amylyx Pharmaceuticals Shares Shoot Up As FDA Extends Review Of NDA For Neurodegenerative Disease Candidate
June 03, 2022
The U.S. Food and Drug Administration (FDA) has extended the review of New Drug Application (NDA) by three months, submitted by Amylyx Pharmaceuticals (NASDAQ: AMLX) for its lead drug candidate AMX0035...
Via
Benzinga
Novavax (NVAX) Stock Falls 25% on FDA Heart Inflammation Warning
June 03, 2022
Novavax (NVAX) stock is falling on Friday after the FDA requested a heart inflammation warning for the company's Covid-19 vaccine.
Via
InvestorPlace
Mid-Day Market Update: Nasdaq Down 300 Points; Turning Point Therapeutics Shares Jump
June 03, 2022
U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping more than 300 points on Friday.
Via
Benzinga
40 Stocks Moving In Friday's Mid-Day Session
June 03, 2022
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
Via
Benzinga
Why Is Amylyx Pharmaceuticals (AMLX) Stock Up 23% Today?
June 03, 2022
Amylyx Pharmaceuticals (AMLX) stock is rising higher on Friday following an update from the U.S. Food and Drug Administration (FDA).
Via
InvestorPlace
Mid-Morning Market Update: Markets Open Lower; US Economy Adds 390,000 Jobs In May
June 03, 2022
U.S. stocks traded lower this morning, with the Dow Jones dropping around 150 points on Friday.
Via
Benzinga
Former Red-Hot IPO Amylyx Soars On New Hopes For Its ALS Drug
June 03, 2022
The FDA pushed its review date for Amylyx Pharmaceuticals' controversial ALS treatment on Friday, and the biotech stock skyrocketed.
Via
Investor's Business Daily
Here's Why Amylyx Pharmaceuticals Shares Are Skyrocketing Today
June 03, 2022
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) shares are trading higher by 37.67% at $13.45 after the company announced the FDA extended the review timeline of the New Drug...
Via
Benzinga
Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS
June 03, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May 31, 2022
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,...
Via
Benzinga
Amylyx Pharmaceuticals Announces Presentation of New Analysis of CENTAUR Trial Results at the European Network to Cure ALS 2022 Meeting
May 26, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2022
May 25, 2022
Upgrades Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of...
Via
Benzinga
Amylyx Pharmaceuticals Announces Publication of Data Showing Randomization to AMX0035 Prolonged Tracheostomy/Ventilation-free Survival and Reduced Occurrence of First Hospitalization
May 16, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Reports First Quarter 2022 Financial Results
May 12, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Announces Publication of New CENTAUR Trial Analyses Further Demonstrating Significant Survival Benefit with AMX0035 in People with ALS
May 05, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
92 Biggest Movers From Friday
May 09, 2022
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the...
Via
Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
April 03, 2022
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...
Via
Benzinga
Amylyx Pharmaceuticals Announces Oral Presentation of Safety and Tolerability Data on AMX0035 from Clinical Trials at 2022 American Academy of Neurology Annual Meeting
April 02, 2022
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Reata Stock Enjoys A Two-Day Climb — Why It Could Still Be Facing Everest
April 01, 2022
One analyst says Reata only has a 50% chance in a neurodegenerative disease.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For April 1, 2022
April 01, 2022
Upgrades
Via
Benzinga
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
March 31, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.